Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa

HIV Infections Clinical Trial

Official title:

The Effectiveness of Antiretroviral Therapy in Reducing the Costs of HIV/AIDS

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00270725
• Other study ID #: RTC-BU-01
• Status: Withdrawn
• Phase: N/A
• First received: December 27, 2005
• Last updated: February 26, 2017
• Start date: July 1, 2005
• Est. completion date: July 1, 2005

Study information

• Verified date: February 2017
• Source: Boston University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine the impact of anti-HIV treatment on the work attendance of employed people in South Africa. The study will enroll participants from a large manufacturing and distribution firm in South Africa.

Description:

Little is known about the economic benefits of providing antiretroviral therapy (ART) for HIV infected patients in sub-Saharan Africa and other resource-limited areas. In South Africa, an increasing number of private sector firms are providing access to ART for their employees. One of the barriers to such action, however, is the lack of available information on the success of ART in restoring workers to full productivity, retaining skilled employees in the workforce, and reducing the costs of medical care and death and disability benefits. HIV infected employees on ART may be absent from work less often than untreated HIV infected employees, but more often than HIV uninfected employees. This study will collect data from an independent HIV/AIDS disease treatment program and a large private sector employer in Johannesburg, South Africa to estimate the benefits and costs for businesses to provide ART to eligible employees.

The study will combine individual-level medical outcome and treatment cost data from the treatment program with data on employee work attendance and retention in the workforce from the participating employer. The work attendance of HIV infected employees enrolled in the HIV/AIDS treatment program (index participants) who are either taking ART or receiving pre-ART care will be compared with each other and with that of HIV uninfected employees. There are no study visits associated with this study; all data will be collected from medical records maintained by the HIV/AIDS treatment program and the participants' employer. The financial costs and benefits of the treatment program for the participating company will also be estimated.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 1, 2005
• Est. primary completion date: July 1, 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for All Participants:

• Employed by participating company for at least 1 year prior to study entry

Inclusion Criteria for Index Participants:

• Enrolled in the HIV/AIDS treatment program offered by the participating company

Exclusion Criteria for Index Participants:

• Enrolled in the HIV/AIDS treatment program prior to 01/01/04 or after 06/30/05

Related Conditions & MeSH terms

• HIV Infections

Locations

Country	Name	City	State
South Africa	Health Economics Research Office, Helen Joseph Hospital	Johannesburg	Gauteng

Sponsors (2)

Lead Sponsor	Collaborator
Boston University	United States Agency for International Development (USAID)

Country where clinical trial is conducted

South Africa, 

References & Publications (2)

Fox MP, Rosen S, MacLeod WB, Wasunna M, Bii M, Foglia G, Simon JL. The impact of HIV/AIDS on labour productivity in Kenya. Trop Med Int Health. 2004 Mar;9(3):318-24. — View Citation

Rosen S, Vincent JR, MacLeod W, Fox M, Thea DM, Simon JL. The cost of HIV/AIDS to businesses in southern Africa. AIDS. 2004 Jan 23;18(2):317-24. — View Citation

External Links

•   Click here for the Program on the Social and Economic Impacts of the AIDS Epidemic Web site